News for ATRS Stock

Hart-Scott-Rodino Waiting Period Expires for Halozyme's Acquisition of Antares Pharma Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader Antares Pharma Announces FDA Approval Of TLANDO™, an Oral Treatment for Testosterone Replacement Therapy Antares Pharma Reports Fourth Quarter and Full-Year 2021 Financial and Operating Results Antares Pharma to Present at the Cowen 42nd Annual Healthcare Conference Antares Pharma To Report Fourth Quarter And Full-Year 2021 Financial And Operating Results Antares Pharma Announces FDA Acceptance of NDA Resubmission for TLANDO® Antares Pharma Receives FDA Fast Track Designation for ATRS-1902 for Adrenal Crisis Rescue Antares Pharma Appoints Claude E. Richardson as Senior Vice President of Human Resources Antares Pharma Announces Positive Results From Phase I Study For ATRS-1902 For Adrenal Crisis Rescue Antares Pharma Announces Divestiture of Otrexup® Antares Pharma to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference Antares Pharma to Present at the Jefferies London Healthcare Conference Antares Pharma Reports Third Quarter 2021 Financial and Operating Results Antares Pharma Announces Appointment of Carmen Volkart to its Board of Directors Antares Pharma Announces Oral Presentation at the 22nd Annual Fall Scientific Meeting of SMSNA Antares Pharma to Report Third Quarter 2021 Financial and Operating Results Antares Pharma Enters into Exclusive License Agreement With Lipocine for TLANDO® in U.S. Antares Pharma Initiates Phase I Study For ATRS-1902 For Adrenal Crisis Rescue Antares Pharma to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference Antares Pharma Reports Second Quarter 2021 Financial and Operating Results Antares Pharma to Report Second Quarter 2021 Financial and Operating Results Antares Pharma Announces FDA Acceptance of IND Application for ATRS-1902 for Adrenal Crisis Rescue Antares Pharma to Present at the Ladenburg Thalmann Annual Healthcare Conference Antares Pharma Announces Partner Idorsia Initiates the Phase 3 Study With Selatogrel for Acute Myocardial Infarction Antares Pharma Announces Submission of IND Application for ATRS-1902 for Adrenal Crisis Rescue Antares Pharma to Present at the Raymond James Human Health Innovations Conference Antares Pharma to Present at the Jefferies Virtual Healthcare Conference Antares Pharma Appoints Joseph Renda as Senior Vice President of Commercial Antares Pharma Reports First Quarter 2021 Financial and Operating Results Antares Pharma Announces Poster Presentation at the Pediatric Endocrine Society 2021 Virtual Annual Meeting Antares Pharma to Participate in the 7th Annual Truist Securities 2021 Life Sciences Summit Antares Pharma to Report First Quarter 2021 Financial and Operating Results Antares Pharma Appoints Dr. Peter Richardson as Executive Vice President, Research and Development and Chief Medical Officer Antares Pharma Reports Fourth Quarter and Full-Year 2020 Financial and Operating Results Antares Pharma to Present at Two Upcoming Investor Conferences Antares Pharma to Report Fourth Quarter and Full-Year 2020 Financial and Operating Results Antares Pharma to Participate in the SVB Leerink 10th Annual Virtual Global Healthcare Conference Antares Pharma Announces Full-Year 2021 Revenue Guidance of $175-200 Million Antares Pharma to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference Antares Pharma to Present at the Jefferies Virtual London Healthcare Conference Antares Pharma Reports Strong Third Quarter 2020 Financial and Operating Results Antares Pharma to Report Third Quarter 2020 Financial and Operating Results Antares Pharma to Present at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference Antares Pharma Appoints Patrick Shea Senior Vice President of Commercial Antares Pharma Reports First Quarter 2020 Operating and Financial Results First Commercial Product Using Antares Pharma’s Multi-Dose Pen Platform Launches in Europe Antares Pharma to Present at the Raymond James Human Health Innovation Conference Antares Pharma to Report First Quarter 2020 Operating and Financial Results